The graded prognostic assessment (GPA) was a great tool to estimate survival in patients with brain metastases--until targeted therapies dramatically altered survival outcomes for many populations. This report updates all the diagnosis-specific GPA’s using data from nearly 7000 patients from 18 institutions treated from 2006 to 2017. Across multiple diagnoses, factors like molecular markers, number of brain mets, and extent of extracranial disease gained in prognostic importance. It’s pretty incredible to compare median survival times to the 2012 report and see that predicted survival has more than double for many diagnoses with dsGPA of 3.5-4.0. | Sperduto, J Clin Oncol 2020


Popular Posts